Prostate cancer vaccine - Pepscan Therapeutics

Drug Profile

Prostate cancer vaccine - Pepscan Therapeutics

Alternative Names: CoVaccine HT/PEP-223; PEP-223/CoVaccine HT

Latest Information Update: 22 May 2012

Price : $50

At a glance

  • Originator Pepscan Systems
  • Developer Pepscan Therapeutics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 22 May 2012 No development reported - Phase-I/II for Prostate cancer in Netherlands (Parenteral)
  • 24 Mar 2009 Prostate cancer vaccine is still in phase I/II trials for Prostate cancer in the Netherlands
  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top